The Pharma Jerk We All Hated Last Month Still Hasn’t Dropped the Price of That Drug


[The title says it all. A smug, greedy, lying little creep. The corporatocracy in full bloom. *RON*]

—By Madison Pauly, Mother Jones, 8 October 2015

Thomas_EyeDesign/iStock
Two weeks ago, Turing Pharmaceuticals CEO Martin Shkreli promised to drop the price of Daraprim, a parasite-fighting drug, after raising it from $13.50 a tablet to $750 a tablet. But so far the price tag hasn't budged.

Shkreli, a former hedge fund manager who acquired Turing in August, first drew criticism after a USA Today article reported the 5,000 percent price hike. He then told ABC News in September that the company would "lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit."

Business Insider writes:
That hasn't happened yet. A 30-day, 30-pill supply of Daraprim would cost me $27,006 at my local pharmacy.
That boils down to about $900 a pill, which includes the wholesale cost, along with specific pharmacy fees based on the zip code I gave the pharmacy.
So while the price of the drug hasn't gotten any higher since Shkreli hiked it 5,000%, it hasn't gotten any lower since he promised to reduce it either. Turing did not respond to Business Insider's request for clarification about this price.

Comments

Popular posts from this blog

Kinder Morgan's $771,000 donation to B.C. Liberals raises red flags while Premier shifts to damage control

Israel and US Hide Names of Companies Supporting Israeli Settlements

Does Even Mark Zuckerberg Know What Facebook Is?